Our research and development efforts are focused on creating safer, more effective Ibogaine derivatives (IbogaLogs) while advancing the scientific foundation for addiction treatment.
Key Objectives:
- Minimizing Cardiac Risks:
- Identify IbogaLogs with reduced potential for cardiac arrhythmia without compromising their therapeutic or psychedelic effects.
- Minimizing Cardiac Risks:
- GMP-Certified Ibogaine Production:
- Ensure the production of Good Manufacturing Practice (GMP) compliant Ibogaine for research and therapeutic use.
- GMP-Certified Ibogaine Production:
- Pre-Clinical Trials:
- Begin rigorous pre-clinical testing to establish safety, efficacy, and pharmacokinetics.
- Pre-Clinical Trials:
- Intellectual Property Strategy:
- Navigate IP pathways, including strategies for IND bypass via foreign clinical use precedents.
- Intellectual Property Strategy:
- Novel IbogaLog Synthesis:
- Identify and transform specific molecular moieties to create new IbogaLog derivatives.
- Novel IbogaLog Synthesis:
- Contraindication Research:
- Investigate potential contraindications with Suboxone and other medications.
- Contraindication Research:
- AI-Guided Chemical Library Development:
- Utilize artificial intelligence to generate a comprehensive digital library of IbogaLog compounds for further study.
- AI-Guided Chemical Library Development:
- Synthetic Pathways and Biochemical Assays:
- Develop cost-effective synthesis strategies and biochemical assays to explore combinational chemistry applications.
- Synthetic Pathways and Biochemical Assays:
- Neuroimaging Innovation:
- Create zebrafish embryo hallucination neuroimaging assays to study psychedelic effects at a molecular level.